<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Current APL chemotherapy protocols usually include high-dose <z:chebi fb="0" ids="48120">anthracyclines</z:chebi>, <z:chebi fb="0" ids="50729">mitoxantrone</z:chebi>, and epipodophillotoxins, which are <z:chebi fb="0" ids="50750">topoisomerase II inhibitors</z:chebi> of high leukemogenic potential </plain></SENT>
<SENT sid="1" pm="."><plain>In the last years, several case reports of <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> (different from APL), occurring during the course of APL have been made </plain></SENT>
<SENT sid="2" pm="."><plain>We report herein a first case of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CMML</z:e> with <z:mp ids='MP_0004026'>monosomy</z:mp> 7 occurring after treatment of APL </plain></SENT>
</text></document>